PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(04): 255-260
DOI: 10.1055/s-0041-1731581
Original Article: Lung Cancer

Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center

Tilak TVSVGK 
1   Department of Internal Medicine, Armed Forces Medical College (AFMC), Pune, Maharashtra, India
,
Ajay Handa
2   Department of Medicine, INHS Asvini, Mumbai, Maharashtra, India
,
Kishore Kumar
3   Department Medicine, Command Hospital Air Force (CHAF), Bangalore, Karnataka, India
,
Deepti Mutreja
4   Department of Pathology, Armed Forces Medical College (AFMC), Pune, Maharashtra, India
,
Shankar Subramanian
1   Department of Internal Medicine, Armed Forces Medical College (AFMC), Pune, Maharashtra, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background Pulmonary toxicity due to chemotherapeutic agents can occur with many established and new drugs. Strong clinical suspicion is important as the clinical presentation is usually with nonspecific symptoms like cough, dyspnea, fever, and pulmonary infiltrates. Timely discontinuation of the offending agent alone can improve the condition.

Methods A prospective observational study on patients receiving chemotherapy at an 800-bedded tertiary care hospital was performed from 2014 to 2016. Consecutive patients on chemotherapy, presenting with nonresolving respiratory symptoms were evaluated with contrast-enhanced computerized tomography of chest, diffusion lung capacity for carbon monoxide (DLCO), fiberoptic bronchoscopy with lavage, and biopsy, after excluding all causes for pulmonary infections. Descriptive data has been depicted.

Results A total of 18 patients were evaluated for persistent symptoms of dry cough, dyspnea, and fever among 624 who received chemotherapy during the study period. Ground-glass opacities on high-resolution CT was the most common imaging finding, others being patchy subpleural consolidation and pleural effusion. Lymphocyte-predominant bronchoalveolar lavage was detected in nine. Eight of the 15 patients who underwent DLCO, had abnormal results. Seven had significant histopathological findings on bronchoscopic lung biopsy, which revealed organizing pneumonia as the most common pattern. Paclitaxel, fluorouracil, gemcitabine, and tyrosine kinase inhibitors were the common culprit drugs. Discontinuation alone of the culprit drug was effective in 15 and 3 needed oral corticosteroids for relief of symptoms. None of the patients died due to the toxicity.

Conclusion An incidence of 2.8% for chemotherapy-induced lung injury was seen in our observational study of 3 years, with parenchymal, interstitial, and pleural involvement due to various chemotherapeutic agents. Oral steroids maybe required in a subset of patients not responding to discontinuation of the culprit agent.

Keywords

chemotherapy-associated pulmonary toxicity - ground-glass opacities - transbronchial lung biopsy - organizing pneumonia


Publikationsverlauf

Artikel online veröffentlicht:
11. November 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133 (02) 528-538
    CrossrefPubMedGoogle Scholar
  • 2 Quigley M, Brada M, Heron C, Horwich A. Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non-Hodgkin’s lymphoma. Hematol Oncol 1988; 6 (04) 319-324
    CrossrefPubMedGoogle Scholar
  • 3 Skubitz KM, Skubitz AP. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998; 9 (01) 45-50
    CrossrefPubMedGoogle Scholar
  • 4 Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004; 25 (01) 53-64
    CrossrefPubMedGoogle Scholar
  • 5 Nakase K, Tsuji K, Nagaya S. et al Acute interstitial pneumonitis during chemotherapy for haematological malignancy. Eur J Cancer Care (Engl) 2005; 14 (04) 336-341
    CrossrefPubMedGoogle Scholar
  • 6 Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L. Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. J Oncol Pharm Pract 2012; 18 (02) 311-315
    CrossrefPubMedGoogle Scholar
  • 7 Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P. Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med 2004; 25 (03) 479-519 vi vi.
    CrossrefPubMedGoogle Scholar
  • 8 O’Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990; 323 (06) 378-382
    CrossrefPubMedGoogle Scholar
  • 9 Leslie KO, Gruden JF, Parish JM, Scholand MB. Transbronchial biopsy interpretation in the patient with diffuse parenchymal lung disease. Arch Pathol Lab Med 2007; 131 (03) 407-423
    CrossrefPubMedGoogle Scholar
  • 10 Erasmus JJ, McAdams HP, Rossi SE. Drug-induced lung injury. Semin Roentgenol 2002; 37 (01) 72-81
    CrossrefPubMedGoogle Scholar
  • 11 Wong P, Leung AN, Berry GJ. et al Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. AJR Am J Roentgenol 2001; 176 (03) 718-720
    CrossrefPubMedGoogle Scholar
  • 12 Fujimori K, Yokoyama A, Kurita Y, Uno K, Saijo N. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998; 55 (04) 340-344
    CrossrefPubMedGoogle Scholar
  • 13 Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997; 31 (12) 1471-1474
    CrossrefPubMedGoogle Scholar
  • 14 Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest 1996; 110 (01) 289-292
    CrossrefPubMedGoogle Scholar
  • 15 Sakurada T, Kakiuchi S, Tajima S. et al Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 2015; 49 (04) 398-404
    CrossrefPubMedGoogle Scholar
  • 16 Shimura T, Fuse N, Yoshino T. et al Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2010; 21 (10) 2005-2010
    CrossrefPubMedGoogle Scholar
  • 17 Galvão FH, Pestana JOM, Capelozzi VL. Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. Cancer Chemother Pharmacol 2010; 65 (03) 607-610
    CrossrefPubMedGoogle Scholar
  • 18 Saito Y, Gemma A. Current status of DILD in molecular targeted therapies. Int J Clin Oncol 2012; 17 (06) 534-541
    CrossrefPubMedGoogle Scholar
  • 19 Radaelli F, Bramanti S, Fantini NN, Fabio G, Greco I, Lambertenghi-Deliliers G. Dasatinib-related alveolar pneumonia responsive to corticosteroids. Leuk Lymphoma 2006; 47 (06) 1180-1181
    CrossrefPubMedGoogle Scholar
  • 20 Luo C, Lv M, Li Y, Liu P, Yang J. Gefitinib-induced interstitial pneumonia: a case report and review of the literature. Exp Ther Med 2014; 7 (04) 855-859
    CrossrefPubMedGoogle Scholar
  • 21 Takada Y, Matsuo K. Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease. Keio J Med 2012; 61 (04) 120-127
    CrossrefPubMedGoogle Scholar
  • 22 Koma Y, Matsuoka H, Yoshimatsu H, Suzuki Y. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review. Int J Clin Pharmacol Ther 2012; 50 (10) 760-764
    CrossrefPubMedGoogle Scholar
  • 23 Takeda M, Okamoto I, Makimura C, Fukuoka M, Nakagawa K. Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. J Thorac Oncol 2010; 5 (07) 1103-1104
    CrossrefPubMedGoogle Scholar
  • 24 Romagnoli M, Bigliazzi C, Casoni G. et al The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25 (01) 36-45
    PubMedGoogle Scholar